Shawn J Kile, M.D.
Investigator
Dr. Shawn Kile is a board-certified neurologist with expertise in treating cognitive disorders. He cares for patients with dementia, traumatic brain injury, autism, encephalopathy, and other neurocognitive illnesses. Dr. Kile has authored numerous publications and presented internationally on new approaches to managing Alzheimer’s disease, dementia, neurobehavioral disorders and traumatic brain injury. He is a Principal Investigator for physician-initiated trials supported by the Sutter Institute for Medical Research (SIMR) and phase 2-3 clinical studies assessing the efficacy of new therapies for Alzheimer’s disease and adult autism.
Publications
View All Publications from PubMed- BMC Neuroscience2099 Dec 31
- Publication
Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment
American Journal of Alzheimer's Disease & Other Dementias2020 Feb 12 - Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009 Nov;30(11):1728-36. doi: 10.1016/j.neurobiolaging.2007.12.021. Epub 2008 Feb 21.J Neurol Neurosurg Psychiatry. 2015 Sep 29. pii: jnnp-2015-311486. doi: 10.1136/jnnp-2015-311486.2015 Sep 29
- Arch Neurol. 2009 Jan;66(1):125-9. doi: 10.1001/archneurol.2008.517. Alzheimer abnormalities of the amygdala with Klüver-Bucy syndrome symptoms: an amygdaloid variant of Alzheimer disease. Kile SJ1, Ellis WG, Olichney JM, Farias S, DeCarli C. Author information 1Department of Neurology, University of California at DavisArch Neurol. 2009 Jan;2009 Jan 20
- Psychopharmacol Bull. 2007;40(4):156-67. Neuropsychiatric update: neuroimaging schizophrenia. Kile SJ.Psychopharmacol Bull. 2007;40(4):156-67. Neuropsychiatric update: neuroimaging schizophrenia. Kile SJ.2007 Jul 20
Research studies
Alzheimer's National Registry for Treatment and Diagnostics (ALZ-NET)
- Research study
Alzheimers/Cognitive Impairment NVI-039 AD
Proof of Concept of the Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment due to Alzheimer’s Disease